Royalty Pharma plc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.62 Intrinsic Value $38.66median of 6 methods · middle span $35-$57based on filings through 30 Jun 2026 Market Price $57.63Price as of 1 Oct 2026 OvervaluedIntrinsic value is 33% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $33.3B Enterprise Value $41.5B Shares Outstanding 551.7M diluted Moat Rating None Next Earnings Date4 Nov 2026 Last ex-dividend14 Aug 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Royalty Pharma entered the second half of 2026 with 14% quarterly Royalty Receipts growth, a second increase to full-year Portfolio Receipts guidance, strong cash generation and more than 35 commercial products plus 19 development-stage candidates. The operating outlook is constructive, but the risk-reward is balanced by $9.2 billion of reported debt, exposure to product-specific patent, generic and biosimilar erosion, and uncertainty around returns from development-stage funding. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$61.00 Mean target$64.75 High · most bullish analyst$70.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $61.0020% Generic or biosimilar erosion and declines in mature products outweigh growth from newer royalties, while one or more development-stage assets fail to generate expected receipts. Weaker cash generation alongside substantial debt reduces capital-deployment flexibility and compresses the value assigned to future portfolio receipts. Base CaseCentral scenario $64.7555% Matches the consensus meanPortfolio Receipts finish within the company's $3.4 billion to $3.5 billion guidance range, with growth products offsetting expected erosion in mature assets. New investments support longer-term diversification, but debt and development risk constrain re-rating. Bull CaseUpside scenario $70.0025% Royalty Receipts remain near or above the upper end of 2026 guidance as Tremfya, Voranigo, Imdelltra and Evrysdi continue strong growth. Regulatory and commercial progress across the 19-candidate development portfolio adds new receipt streams, while disciplined deployment converts strong portfolio cash flow into additional royalties. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |